|Bid||18.50 x 800|
|Ask||20.02 x 3200|
|Day's range||19.96 - 20.12|
|52-week range||16.10 - 21.61|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||24.66|
|Forward dividend & yield||0.83 (4.13%)|
|Ex-dividend date||25 Sep 2019|
|1y target est||24.37|
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") will provide an update on the progress of its business transformation and priorities today at the 38th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber, will share details on Takeda’s portfolio and pipeline strategy, financial outlook, and ongoing sustainability efforts, including its newly established commitment to carbon neutrality across its value chain.
Japan's exports slipped for a 12th straight month in November, as declining shipments to the United States and China hit the trade-reliant economy, raising the risk of a fourth-quarter contraction. Official data released on Wednesday showed Japan's exports fell 7.9% year-on-year in November, a smaller decline than the 8.6% decline expected by economists in a Reuters poll.
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL).
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) ("Takeda"), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis.
− Data presented from the pivotal Phase 3 trial include an update on overall efficacy of the vaccine candidate, as well as formal analyses of secondary efficacy endpoints by seroty
An additional six months of data from a late-stage trial of Takeda Pharmaceutical Co's experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group, researchers said on Saturday. The longer-term data, presented at the American Society of Tropical Medicine and Hygiene meeting in Maryland, also showed a slight waning of the overall effectiveness of the vaccine, TAK-003. Initial results, published this month in the New England Journal of Medicine, showed the vaccine succeeded overall but failed to protect against dengue 3 in children and teens who had never previously been exposed to the mosquito-borne disease.
– ALUNBRIG Reduced the Risk of Disease Progression or Death by 76% in Patients whose Disease Had Spread to the Brain, and by 57% in All Patients, when Compared to Crizotinib –
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
− Growth in the near- and medium-term will also be driven by the expansion of Takeda’s current 14 global growth brands
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Data Presented at the 2019 American College of Allergy, Asthma and Immunology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. NINLARO is currently not approved for this specific use.
− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate
– Company Leadership to Present 20 Abstracts in Oncology and Nine in Hematology Throughout Conference, Showcasing Takeda’s Unique Expertise in Blood Cancers and Bleeding Disorders
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers. Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop and commercialize up to four programs, including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy. Takeda and MD Anderson will also conduct a research collaboration to further develop these CAR NK programs.
The portfolio, which Takeda is selling in a push to slash debt after its $59 billion purchase of Shire, includes drugs sold exclusively in Russia, Georgia and a number of countries from within the Commonwealth of Independent States, the companies said. The deal follows Monday's announcement of Stada's acquisition of Czech Republic-based Walmark, a consumer health products business serving mainly eastern Europe. Stada and the owner of Walmark, buyout firm Mid Europa Partners, did not say how much the deal was worth.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”), an international pharmaceutical company, for a total value of $660 million USD. The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth & Emerging Markets Business Unit. This is Takeda’s fourth divestment transaction in the past six months that contributes to the Company’s goal to divest approximately $10 billion USD in non-core assets to focus on its five key business areas and commitment to accelerating its deleveraging following its acquisition of Shire.
OSAKA, Japan-- -- FY2019 H1 revenue 1660.2 billion yen, up +88.5% versus prior year mainly due to acquisition of Shire and solid performance of 14 global growth brands Strong core operating profit * of 541.6 billion yen, up +155.5% versus FY2018 H1 and Underlying Core Operating Profit Margin of 32.2% driven by synergies, OPEX, and improved product mix Raising full year profit guidance to reflect strong ...